Disclaimer: If one chooses to supplement with a given compound, ultimately, the responsibility is on him/her to make sure they are well informed. This author feels that there is no substitute to making decisions based on guidelines set by professionals with experience using LGD-4033.
This post is a summary based on human clinical trials published and peer reviewed, assessing the effects and safety of a low dose (1mg/day was the highest dose given), short term (3 weeks) use of LGD-4033. Bear in mind that this compound may safely be used is much greater dosage for much greater timeframe to yield greater effects.
Utilizing the gold standard DEXA scan, the lean body mass increased proportionately with increasing LGD-4033 dose. Subjects gained on average 2.6lb of lean mass without dietary or exercise lifestyle modification (!!!)
The gold standard of side effect profiling is comparing any drugs to a placebo control group. In this study, there was no difference between the control group treated with placebo and the group treated with LGD-4033. No liver damage was observed as well as, interestingly, no observed effect on the prostate in males of ages 20-51.
After treatment discontinuation, all hormone levels and lipid profiles returned to normal in the group treated with LGD-4033
*LGD-4033 was observed to cause a small level of "shutdown", however, this level is in no way comparable to the one observed by AAS.
Even more mindblowing is that the LGD-4033 treated group did not receive any PCT and yet, all hormone profiles normalized in all subjects in less than two months time, at the most.
**This does not mean a PCT may not be required, please adhere to proper advice dispensed by experienced SARM protocol experts
"The study also revealed other attractive PK (pharmacokinetic) attributes of the drug—including a prolonged circulating half-life... and robust relationships between the dose and outcomes"
"it is particularly remarkable that significant dose-dependent gains in LBM (Lean Body Mass) were evident in this short duration, indicating this SARM’s substantial androgenic–anabolic activity on the skeletal muscle."
"LGD-4033 has been shown to increase bone mineral density, periosteal bone formation, and femur bending strength in preclinical models"
Thank you for reading.
References
The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men;
Shehzad Basaria, Lauren Collins, E. Lichar Dillon, Katie Orwoll, Thomas W. Storer, Renee Miciek, Jagadish Ulloor, Anqi Zhang, Richard Eder, Heather Zientek, Gilad Gordon, Syed Kazmi, Melinda Sheffield-Moore, Shalender Bhasin;
ournals of Gerontology Series A: Biological Sciences and Medical Sciences
This post is a summary based on human clinical trials published and peer reviewed, assessing the effects and safety of a low dose (1mg/day was the highest dose given), short term (3 weeks) use of LGD-4033. Bear in mind that this compound may safely be used is much greater dosage for much greater timeframe to yield greater effects.
LGD-4033 effects on body composition
Utilizing the gold standard DEXA scan, the lean body mass increased proportionately with increasing LGD-4033 dose. Subjects gained on average 2.6lb of lean mass without dietary or exercise lifestyle modification (!!!)
LGD-4033 was associated with virtually no side effects
The gold standard of side effect profiling is comparing any drugs to a placebo control group. In this study, there was no difference between the control group treated with placebo and the group treated with LGD-4033. No liver damage was observed as well as, interestingly, no observed effect on the prostate in males of ages 20-51.
After treatment discontinuation, all hormone levels and lipid profiles returned to normal in the group treated with LGD-4033
*LGD-4033 was observed to cause a small level of "shutdown", however, this level is in no way comparable to the one observed by AAS.
Even more mindblowing is that the LGD-4033 treated group did not receive any PCT and yet, all hormone profiles normalized in all subjects in less than two months time, at the most.
**This does not mean a PCT may not be required, please adhere to proper advice dispensed by experienced SARM protocol experts
Additional insight from this human trial study
"The study also revealed other attractive PK (pharmacokinetic) attributes of the drug—including a prolonged circulating half-life... and robust relationships between the dose and outcomes"
"it is particularly remarkable that significant dose-dependent gains in LBM (Lean Body Mass) were evident in this short duration, indicating this SARM’s substantial androgenic–anabolic activity on the skeletal muscle."
"LGD-4033 has been shown to increase bone mineral density, periosteal bone formation, and femur bending strength in preclinical models"
Thank you for reading.
References
The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men;
Shehzad Basaria, Lauren Collins, E. Lichar Dillon, Katie Orwoll, Thomas W. Storer, Renee Miciek, Jagadish Ulloor, Anqi Zhang, Richard Eder, Heather Zientek, Gilad Gordon, Syed Kazmi, Melinda Sheffield-Moore, Shalender Bhasin;
ournals of Gerontology Series A: Biological Sciences and Medical Sciences
Last edited:
